Posted by Michael Wonder on 10 Jul 2026
FDA approves Ennumo (pegfilgrastim-pccg), Accord BioPharma's second pegfilgrastim biosimilar to Neulasta (pegfilgrastim)
9 July 2026 - ire/ -- Accord BioPharma announced today that the US FDA has approved Ennumo (pegfilgrastim-pccg), a biosimilar to Neulasta (pegfilgrastim).
Ennumo is indicated in adults and paediatric patients aged newborn and older to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia, and to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome).
